RxDoctor Payments Data

Amanda Gartner, APRN

Nurse Practitioner · San Antonio, TXNPI 1821757311

Payments from drug & device makers

$5,245in general payments, 2019–2025

Across 105 payments — averaging $49.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Inari Medical, Inc.$649
  • Boston Scientific$431
  • Johnson & Johnson$406
  • Abiomed$336
  • Novo Nordisk$308
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,14698%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,245 in reported general payments places this provider in the 90th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$13,008
Medicare patients
200
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$123,561
EntrestoSacubitril/Valsartan47$63,760
XareltoRivaroxaban28$42,296
JardianceEmpagliflozin20$18,568
FarxigaDapagliflozin Propanediol11$14,864
Nebivolol Hcl93$6,015
Metoprolol Succinate159$1,812
Losartan Potassium121$1,718
Atorvastatin Calcium192$1,693
Rosuvastatin Calcium127$1,439
Telmisartan46$1,306
Bumetanide14$1,285
Ezetimibe63$1,157
Carvedilol142$1,064
Amlodipine Besylate120$840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$99$123,561105 claims
NovartisEntresto$292$63,76047 claims
Johnson & JohnsonXarelto$406$42,29628 claims
AstraZenecaFarxiga$157$14,86411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →